Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:41 AM
Ignite Modification Date: 2025-12-25 @ 12:41 AM
NCT ID: NCT03439267
Eligibility Criteria: Inclusion Criteria: 1. Male subjects 50 to 80 years of age or female subjects 60 to 80 years of age, of any ethnic origin 2. Ability to understand and provide agreement to study participation, which must be obtained prior to initiation of any study procedures 3. No known history, as documented in the EHR, of coronary artery disease, cerebrovascular disease, peripheral vascular disease, or diabetes mellitus at enrollment 4. Willing and able to provide access to their EHR until study end 5. Willing and able to undergo a computed tomography (CT) coronary artery calcium screening test 6. Current and/or past patients seen at Intermountain facilities and who have accessible EHR at the facility(ties) where they are seen. Exclusion Criteria: 1. Patients who have active on-going cancer or are on dialysis 2. Any evidence of statin use prior to study participation 3. Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study 4. Any evidence of a CAC test within the last 5 years prior to screening 5. The Study Doctor(s) determine(s) that the subject is not eligible for participation in this research study 6. The subject is non-English speaking, and therefore may be unable to fully understand the written and spoken instructions that may relate to the proper conduct of the trial
Healthy Volunteers: True
Sex: ALL
Minimum Age: 50 Years
Maximum Age: 80 Years
Study: NCT03439267
Study Brief:
Protocol Section: NCT03439267